Trials / Completed
CompletedNCT04695769
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- Helwan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin | Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks. |
| DRUG | Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] | Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks. |
Timeline
- Start date
- 2020-11-21
- Primary completion
- 2021-10-21
- Completion
- 2021-10-21
- First posted
- 2021-01-05
- Last updated
- 2022-09-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04695769. Inclusion in this directory is not an endorsement.